Latest Articles

Lp(a) as ASCVD risk factor

ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci

The role of the patient in Achieving LDL-C Target

Lipid Management in Patients with Diabetes Mellitus

Approach for Patients with PAD and T2D: Focus on LDL-C Control

PCSK9i and Prevention of CVD

The synopsis of a Cochrane Systematic review on PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

FeNO Is a Clinically Useful Biomarker of Type 2 Inflammation in Pediatric Patients With Asthma

What gives you confidence that Dupixent improves patients’ quality of life?

Implementing Beyfortus successfully